Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response

James M Foran, D. Cunningham, B. Coiffier, P. Solal-Celigny, F. Reyes, M. Ghielmini, P. W M Johnson, C. Gisselbrecht, M. Bradburn, J. Matthews, T. A. Lister

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Background: A retrospective analysis was performed to delineate the factors associated with response, and to determine the duration of response, in 87 patients with CD20-positive mantle-cell lymphoma (MCL) treated with Rituximab (chimeric monoclonal anti-CD20 antibody) in two prior studies. Patients and methods: Patients with newly-diagnosed MCL (MCL1, n = 37), and previously-treated MCL (MCL2, n = 50), received single-agent Rituximab, in the context of two multicentre clinical studies using different schedules and doses, conducted in 1996 and 1997. A follow-up analysis was performed at the end of 1998, including all 81 patients who completed therapy. Statistical modeling of factors associated with response was performed using ordered logistic regression. The duration of complete (CR) and partial response (PR), and the time to disease progression (TTP), were also derived. Results: The overall response rate (RR) was 34% (30 of 87) (81 evaluable patients, RR 37%; CR 14%), and was equivalent for MCL1 and MCL2. On univariate analysis, elevated LDH (P = 0.004); prior therapy with alkylating agents (P = 0.01) or fludarabine phosphate (P = 0.04); WHO performance status = 2 (P = 0.02); MCL2 refractory to last prior therapy (P = 0.04); and splenomegaly (P = 0.04), each at the time of treatment with Rituximab, were significantly associated with a lower RR. On multivariate analysis, only LDH (P = 0.007) and prior alkylating agents (P = 0.03) retained statistical significance. At a median follow-up of 1.4 years, the median TTP was 7 months. The median duration of response was one year, and was significantly longer for patients achieving CR vs. PR (P = 0.04). Conclusions: Rituximab is active in MCL, and can induce complete responses in a minority of patients. Elevated LDH at the time of therapy, and prior therapy with alkylating agents, are associated with a significantly lower RR. The duration of response of one year is similar to that previously reported in follicular lymphoma.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume11
Issue numberSUPPL. 1
StatePublished - 2000
Externally publishedYes

Fingerprint

Mantle-Cell Lymphoma
Statistical Factor Analysis
Anti-Idiotypic Antibodies
Monoclonal Antibodies
Alkylating Agents
fludarabine phosphate
Therapeutics
Disease Progression
Follicular Lymphoma
Splenomegaly
Rituximab
Reaction Time
Multicenter Studies
Appointments and Schedules
Multivariate Analysis
Logistic Models

Keywords

  • Anti-CD20
  • Chimeric monoclonal antibody
  • Mantle-cell lymphoma
  • R.E.A.L. Classification
  • Rituximab

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Foran, J. M., Cunningham, D., Coiffier, B., Solal-Celigny, P., Reyes, F., Ghielmini, M., ... Lister, T. A. (2000). Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response. Annals of Oncology, 11(SUPPL. 1).

Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody) : Analysis of factors associated with response. / Foran, James M; Cunningham, D.; Coiffier, B.; Solal-Celigny, P.; Reyes, F.; Ghielmini, M.; Johnson, P. W M; Gisselbrecht, C.; Bradburn, M.; Matthews, J.; Lister, T. A.

In: Annals of Oncology, Vol. 11, No. SUPPL. 1, 2000.

Research output: Contribution to journalArticle

Foran, JM, Cunningham, D, Coiffier, B, Solal-Celigny, P, Reyes, F, Ghielmini, M, Johnson, PWM, Gisselbrecht, C, Bradburn, M, Matthews, J & Lister, TA 2000, 'Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response', Annals of Oncology, vol. 11, no. SUPPL. 1.
Foran, James M ; Cunningham, D. ; Coiffier, B. ; Solal-Celigny, P. ; Reyes, F. ; Ghielmini, M. ; Johnson, P. W M ; Gisselbrecht, C. ; Bradburn, M. ; Matthews, J. ; Lister, T. A. / Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody) : Analysis of factors associated with response. In: Annals of Oncology. 2000 ; Vol. 11, No. SUPPL. 1.
@article{8087f3271d634ddc84f72020dc293f00,
title = "Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response",
abstract = "Background: A retrospective analysis was performed to delineate the factors associated with response, and to determine the duration of response, in 87 patients with CD20-positive mantle-cell lymphoma (MCL) treated with Rituximab (chimeric monoclonal anti-CD20 antibody) in two prior studies. Patients and methods: Patients with newly-diagnosed MCL (MCL1, n = 37), and previously-treated MCL (MCL2, n = 50), received single-agent Rituximab, in the context of two multicentre clinical studies using different schedules and doses, conducted in 1996 and 1997. A follow-up analysis was performed at the end of 1998, including all 81 patients who completed therapy. Statistical modeling of factors associated with response was performed using ordered logistic regression. The duration of complete (CR) and partial response (PR), and the time to disease progression (TTP), were also derived. Results: The overall response rate (RR) was 34{\%} (30 of 87) (81 evaluable patients, RR 37{\%}; CR 14{\%}), and was equivalent for MCL1 and MCL2. On univariate analysis, elevated LDH (P = 0.004); prior therapy with alkylating agents (P = 0.01) or fludarabine phosphate (P = 0.04); WHO performance status = 2 (P = 0.02); MCL2 refractory to last prior therapy (P = 0.04); and splenomegaly (P = 0.04), each at the time of treatment with Rituximab, were significantly associated with a lower RR. On multivariate analysis, only LDH (P = 0.007) and prior alkylating agents (P = 0.03) retained statistical significance. At a median follow-up of 1.4 years, the median TTP was 7 months. The median duration of response was one year, and was significantly longer for patients achieving CR vs. PR (P = 0.04). Conclusions: Rituximab is active in MCL, and can induce complete responses in a minority of patients. Elevated LDH at the time of therapy, and prior therapy with alkylating agents, are associated with a significantly lower RR. The duration of response of one year is similar to that previously reported in follicular lymphoma.",
keywords = "Anti-CD20, Chimeric monoclonal antibody, Mantle-cell lymphoma, R.E.A.L. Classification, Rituximab",
author = "Foran, {James M} and D. Cunningham and B. Coiffier and P. Solal-Celigny and F. Reyes and M. Ghielmini and Johnson, {P. W M} and C. Gisselbrecht and M. Bradburn and J. Matthews and Lister, {T. A.}",
year = "2000",
language = "English (US)",
volume = "11",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody)

T2 - Analysis of factors associated with response

AU - Foran, James M

AU - Cunningham, D.

AU - Coiffier, B.

AU - Solal-Celigny, P.

AU - Reyes, F.

AU - Ghielmini, M.

AU - Johnson, P. W M

AU - Gisselbrecht, C.

AU - Bradburn, M.

AU - Matthews, J.

AU - Lister, T. A.

PY - 2000

Y1 - 2000

N2 - Background: A retrospective analysis was performed to delineate the factors associated with response, and to determine the duration of response, in 87 patients with CD20-positive mantle-cell lymphoma (MCL) treated with Rituximab (chimeric monoclonal anti-CD20 antibody) in two prior studies. Patients and methods: Patients with newly-diagnosed MCL (MCL1, n = 37), and previously-treated MCL (MCL2, n = 50), received single-agent Rituximab, in the context of two multicentre clinical studies using different schedules and doses, conducted in 1996 and 1997. A follow-up analysis was performed at the end of 1998, including all 81 patients who completed therapy. Statistical modeling of factors associated with response was performed using ordered logistic regression. The duration of complete (CR) and partial response (PR), and the time to disease progression (TTP), were also derived. Results: The overall response rate (RR) was 34% (30 of 87) (81 evaluable patients, RR 37%; CR 14%), and was equivalent for MCL1 and MCL2. On univariate analysis, elevated LDH (P = 0.004); prior therapy with alkylating agents (P = 0.01) or fludarabine phosphate (P = 0.04); WHO performance status = 2 (P = 0.02); MCL2 refractory to last prior therapy (P = 0.04); and splenomegaly (P = 0.04), each at the time of treatment with Rituximab, were significantly associated with a lower RR. On multivariate analysis, only LDH (P = 0.007) and prior alkylating agents (P = 0.03) retained statistical significance. At a median follow-up of 1.4 years, the median TTP was 7 months. The median duration of response was one year, and was significantly longer for patients achieving CR vs. PR (P = 0.04). Conclusions: Rituximab is active in MCL, and can induce complete responses in a minority of patients. Elevated LDH at the time of therapy, and prior therapy with alkylating agents, are associated with a significantly lower RR. The duration of response of one year is similar to that previously reported in follicular lymphoma.

AB - Background: A retrospective analysis was performed to delineate the factors associated with response, and to determine the duration of response, in 87 patients with CD20-positive mantle-cell lymphoma (MCL) treated with Rituximab (chimeric monoclonal anti-CD20 antibody) in two prior studies. Patients and methods: Patients with newly-diagnosed MCL (MCL1, n = 37), and previously-treated MCL (MCL2, n = 50), received single-agent Rituximab, in the context of two multicentre clinical studies using different schedules and doses, conducted in 1996 and 1997. A follow-up analysis was performed at the end of 1998, including all 81 patients who completed therapy. Statistical modeling of factors associated with response was performed using ordered logistic regression. The duration of complete (CR) and partial response (PR), and the time to disease progression (TTP), were also derived. Results: The overall response rate (RR) was 34% (30 of 87) (81 evaluable patients, RR 37%; CR 14%), and was equivalent for MCL1 and MCL2. On univariate analysis, elevated LDH (P = 0.004); prior therapy with alkylating agents (P = 0.01) or fludarabine phosphate (P = 0.04); WHO performance status = 2 (P = 0.02); MCL2 refractory to last prior therapy (P = 0.04); and splenomegaly (P = 0.04), each at the time of treatment with Rituximab, were significantly associated with a lower RR. On multivariate analysis, only LDH (P = 0.007) and prior alkylating agents (P = 0.03) retained statistical significance. At a median follow-up of 1.4 years, the median TTP was 7 months. The median duration of response was one year, and was significantly longer for patients achieving CR vs. PR (P = 0.04). Conclusions: Rituximab is active in MCL, and can induce complete responses in a minority of patients. Elevated LDH at the time of therapy, and prior therapy with alkylating agents, are associated with a significantly lower RR. The duration of response of one year is similar to that previously reported in follicular lymphoma.

KW - Anti-CD20

KW - Chimeric monoclonal antibody

KW - Mantle-cell lymphoma

KW - R.E.A.L. Classification

KW - Rituximab

UR - http://www.scopus.com/inward/record.url?scp=0006818262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0006818262&partnerID=8YFLogxK

M3 - Article

C2 - 10707792

AN - SCOPUS:0006818262

VL - 11

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 1

ER -